Please feel free to click through the publications below. We have made available all publications which have been released publicly. Those which are not downloadable will be made available as soon as possible.
NaV channel variants in patients with painful and nonpainful peripheral neuropathy×
NaV channel variants in patients with painful and nonpainful peripheral neuropathy
Samir Wadhawan, PhD, Saumya Pant, PhD, Ryan Golhar, PhD, Stefan Kirov, PhD, John Thompson, PhD, Leslie Jacobsen, MD, Irfan Qureshi, MD, Senda Ajroud-Driss, MD, Roy Freeman, MD, David M. Simpson, MD, A. Gordon Smith,, MD, FAAN, Ahmet Hoke, PhD, MD, Linda J. Bristow, PhD
Objective: To examine the incidence of nonsynonymous missense variants in SCN9A (NaV1.7), SCN10A (NaV1.8), and SCN11A (NaV1.9) in patients with painful and nonpainful peripheral neuropathy.
Methods: Next-generation sequencing was performed on 457 patient DNA samples provided by the Peripheral Neuropathy Research Registry (PNRR). The patient diagnosis was as follows: 278 idiopathic peripheral neuropathy (67% painful and 33%nonpainful) and 179 diabetic distal polyneuropathy (77% painful and 23% nonpainful).
Results: We identified 36 (SCN9A), 31 (SCN10A), and 15 (SCN11A) nonsynonymous missense variants, with 47.7% of patients carrying a low-frequency (minor allele frequency ,5%) missense variant in at least 1 gene. The incidence of previously reported gain-of-function missense variants was low (#3%), and these were detected in patients with and without pain. There were no significant differences in missense variant allele frequencies of any gene, or SCN9A haplotype frequencies, between PNRR patients with painful or nonpainful peripheral neuropathy. PNRR patient SCN9A and SCN11A missense variant allele frequencies were not significantly different from the Exome Variant Server, European American (EVS-EA) reference population. For SCN10A, there was a significant increase in the alternate allele frequency of the common variant p.V1073A and low-frequency variant pS509P in PNRR patients compared with EVS-EA and the 1000 Genomes European reference populations.
Conclusions: These results suggest that identification of a genetically defined subpopulation for testing of NaV1.7 inhibitors in patients with peripheral neuropathy is unlikely and that additional factors, beyond expression of previously reported disease “mutations,” are more important for the development of painful neuropathy than previously discussed. Neurol Genet 2017;3:e207; doi: 10.1212/NXG.0000000000000207
Peripheral Neuropathy Research Registry: A prospective cohort×
Peripheral Neuropathy Research Registry: A prospective cohort
Simone Thomas Senda Ajroud‐Driss Mazen M. Dimachkie Christopher Gibbons Roy Freeman David M. Simpson J. Robinson Singleton A. Gordon Smith PNRR Study Group Ahmet Höke
The Peripheral Neuropathy Research Registry (PNRR) is a prospective cohort of peripheral neuropathy (PN) patients focused on idiopathic axonal peripheral neuropathy. Patients with diabetic, human immunodeficiency virus‐, and chemotherapy‐induced peripheral neuropathies are enrolled as comparison groups. The PNRR is a multi‐center collaboration initiated and funded by the Foundation for Peripheral Neuropathy (FPN) with the objective to recruit a well characterized cohort of patients with different phenotypes and symptoms in each diagnostic category, and to advance research through development of biomarkers and identification of previously unknown causes of PN. The overall goal of the initiative is to find disease‐altering treatments and better symptom relief for patients. We present the study design, types of data collected, and characteristics of the first 1150 patients enrolled. We also discuss ongoing analyses on this dataset, including untargeted‐omics methodologies.
Vitamin B6 levels do not correlate with severity of neuropathy in chronic idiopathic axonal polyneuropathy×
Vitamin B6 levels do not correlate with severity of neuropathy in chronic idiopathic axonal polyneuropathy
Sarah L. Stewart Simone Thomas Erol Höke David Simpson J. Robinson Singleton Ahmet Höke
Pyridoxine (vitamin B6) toxicity is known to cause a length-dependent, sensory predominant axonal polyneuropathy. There is debate regarding the threshold at which intake levels can cause neurological symptoms through pyridoxine toxicity. We asked if elevated plasma vitamin B6 levels were related to outcome measures in a well-characterized cohort of patients with chronic idiopathic axonal polyneuropathy (CIAP). We included 261 patients enrolled in the Peripheral Neuropathy Research Registry who had a complete dataset including a plasma vitamin B6 value. Patients with vitamin B6 deficiency (0-4.9 μg/L) were excluded. We performed a chi-square test for independence and analyzed the logistic relation of elevated plasma B6 level to nerve conduction studies (NCS), neurological examination findings, and patient-reported symptoms controlling for age and time elapsed since neuropathy symptom onset. Plasma B6 level was not related to neuropathy severity. There was no logistic relation of elevated plasma B6 level to NCS results, examination features including toe strength, vibration sense, and deep tendon reflexes, or patient-reported numbness or pain intensity. This study suggests that moderately elevated plasma B6 levels, even in the 100 to 200 μg/L range, are not associated with significantly worse neuropathy signs or symptoms. Although standard supplementation of B6 does not appear to have a major negative affect on CIAP, this study does not directly answer whether stopping supplementation will have a beneficial effect. Very few patients in the study had vitamin B6 levels >300 μg/L, suggesting that screening for vitamin B6 toxicity may be left to the discretion of the physician.